The investigational drugs E7820, indisulam and tasisulam (aryl-sulfonamides) 13 promote the degradation of the splicing factor RBM39 in a proteasome-dependent mechanism. 14 While the activity critically depends on the Cullin RING ligase substrate receptor DCAF15, the 15 molecular details remain elusive. Here we present the cryo-EM structure of the DDB1-DCAF15-16 DDA1 core ligase complex bound to RBM39 and E7820 at 4.4 Å resolution, together with 17 crystal structures of engineered subcomplexes. We show that DCAF15 adopts a novel fold 18 stabilized by DDA1, and that extensive protein-protein contacts between the ligase and substrate 19 mitigate low affinity interactions between aryl-sulfonamides and DCAF15. Our data 20 demonstrates how aryl-sulfonamides neo-functionalize a shallow, non-conserved pocket on 21 DCAF15 to selectively bind and degrade RBM39 and the closely related splicing factor RBM23 22
without the requirement for a high affinity ligand, which has broad implications for the de novo 23 discovery of molecular glue degraders. Pharmacologic intervention for many newly discovered disease targets -such as 26 transcription factors, multi-protein complexes or scaffold proteins -is challenging because they 27 lack an enzymatic function to facilitate the design of classical low molecular weight inhibitors. 28 An alternative approach, small molecule-induced protein degradation, circumvents the need for 29 an enzymatic function in the target protein 1 . The therapeutic potential of targeted protein 30 degradation has been demonstrated by the success of thalidomide-related anti-cancer drugs 31 (often referred to as immunomodulatory drugs, or IMiDs). IMiDs bind CRBN, the substrate 32 receptor of the CUL4-RBX1-DDB1-CRBN (CRL4 CRBN ) E3 ubiquitin ligase 2-5 , and generate a 33 novel binding surface to recruit and ubiquitinate neo-substrates [6] [7] [8] [9] [10] . Such molecular glues present 34 an opportunity to target virtually any protein for degradation, even in the absence of a defined 35 binding pocket. However, IMiDs have nanomolar affinity for CRBN, and the almost invariable 36 conservation of the drug binding pocket and neo-substrate interaction surface suggests that 37 IMiDs hijack an evolutionarily conserved mechanism, akin to what was found for the plant 38 hormones auxin and jasmonate 11, 12 . Whether molecular glue degraders critically depend on such 39 high affinity interactions, and if these interactions can be achieved for ligases that have not 40 evolved for ligand binding, is of critical importance for the further development of this new 41 therapeutic modality. 42 Recently, the aryl-sulfonamides E7820, indisulam and tasisulam were shown to induce 43 targeted degradation of the splicing factor RBM39 through recruitment of the E3 ubiquitin ligase 44 CUL4-RBX1-DDB1-DCAF15 (CRL4 DCAF15 ) 13, 14 , which suggested a molecular glue mechanism. 45 Indisulam was initially discovered in a phenotypic screen and found to be cytotoxic to specific 46 cancer cell lines and in pre-clinical models 15 , while tasisulam and E7820 are derivatives around 47 the sulfonamide core. E7820, indisulam and tasisulam were investigated in multiple phase I and 48 4 II clinical trials involving advanced-stage solid tumors with a modest number of clinical 49 responses, potentially due to an insufficient understanding of the mechanism of action and lack 50 of informed patient stratification 14, 16 . However, novel genetic dependencies in acute myeloid 51 leukemia (AML) suggest a potential for clinical development 16 , and a recent phase II study 52 encourages development with appropriate biomarkers 17 . Moreover, the aryl-sulfonamides appear 53 to promote binding of DCAF15 to the RNA recognition motif (RRM) of RBM39, which 54 suggests that derivatives of the aryl-sulfonamides may be used to target other RRM-containing 55 proteins 9,10 . However, a detailed picture of the mechanism by which sulfonamides engage 56 CRL4 DCAF15 to promote turnover of the neo-substrate RBM39 is critically required to further 57 leverage this new class of drugs for the targeting of RBM39, more generally of RRM containing 58 proteins, and for the broad application of molecular glue degraders. We therefore set out to 59 dissect the molecular basis of RBM39 recruitment to CRL4 DCAF15 . 60 61
Results

62
RBM39 recruitment to CRL4 DCAF15 depends on sulfonamides
63
A recent study identified resistance mutations in cells treated with cytotoxic doses of 64 indisulam that arise in the second RRM domain of RBM39 (RBM39RRM2) 13, 14 . These mutations 65 abrogate the interaction with CRL4 DCAF15 , which suggested that ligase binding is mediated by the 66 RRM2 domain. To better characterize the interaction of RBM39 with DCAF15, we measured the 67 affinity of recombinant DDB1-DCAF15 for RBM39RRM2 in the presence of E7820 using time-68 resolved fluorescence resonance energy transfer (TR-FRET). In the presence of E7820, 69 indisulam or tasisulam at 50 µM, DDB1-DCAF15 and RBM39RRM2 associated with KD app of 2.0 70 µM, 2.1 µM, and 3.5 µM, respectively ( Fig. 1a, Supplementary Fig. 1a ). In contrast, 71 5 RBM39RRM2 did not show measurable affinity with DDB1-DCAF15, even at 10 µM, in the 72 absence of compound ( Supplementary Fig. 1b ). E7820 interacts with DCAF15 (KD app of 3.8 73 µM), but not with RBM39 ( Fig. 1b, Supplementary Fig. 1c ). Based on TR-FRET competition 74 assays ( Supplementary Fig. 1d,e ), E7820 binds to DCAF15 with a Ki of 2.9 µM, while the Ki 75 for indisulam and tasisulam is > 50 µM ( Fig. 1c) , which is analogous to the EC50 values when 76 each compound is titrated into the RBM39RRM2 TR-FRET recruitment assay (Supplementary 77 Fig. 1f ). Notably, RBM39 was potently degraded in cells at 500 nM E7820 (Supplementary 78 Fig. 1g ), which contrasts the relatively weak affinity of E7820 for DCAF15.
80
Cryo-EM structure of DCAF15 complex bound to RBM39RRM2 81 All initial attempts to crystallize full-length human DCAF15 complexes were 82 unsuccessful, so we focused our efforts on cryo-electron microscopy (cryo-EM). Initial class 83 averages of DDB1-DCAF15-E7820-RBM39RRM2, indicated that DCAF15 and the BPB domain 84 of DDB1 were flexible with respect to the core of DDB1 ( Supplementary Fig. 2a-d) . We 85 therefore took advantage of a DDB1 construct lacking the BPB domain, DDB1∆B 18 , and 86 chemical crosslinking ( Supplementary Fig. 2e ). DDB1∆B-DCAF15-DDA1-RBM39RRM2 were 87 co-expressed in the presence of E7820, and after extensive optimization (see Online Methods), 88 we collected a dataset that led to a 3D reconstruction of the 180 kDa complex at an overall 89 resolution of ~ 4.4 Å ( Fig. 1d-f, Supplementary Fig. 2e-h, and Supplementary Fig. 3 ).
90
DDB1∆B was readily placed into the density using the crystal structure (pdb: 5fqd, chain 91 A) as a model, and a search using the balbes-molrep pipeline 19 located the RRM domain 92 corresponding to RBM39RRM2 ( Fig. 1e ) but did not identify homologous structures in the 93 putative full-length DCAF15 density. The map allowed for segmentation of the density and 94 6 unambiguous assignment of density to DCAF15 and DDA1 ( Fig. 1d,e ). While the resolution was 95 not sufficient to build an atomic model ( Supplementary Fig. 3a ), we were able to build an 96 approximate poly-alanine trace of DCAF15 and DDA1 using additional information from cross-97 linking mass spectrometry ( Supplementary Table 1 ), mutations placed in putative helices 98 ( Supplementary Fig. 4a ), and secondary structure prediction. RBM39RRM2 packs against an a-99 helix of DCAF15, and the Gly268 of RBM39, previously found to be a dominant position of 100 indisulam resistance mutations 13, 14 , packs against the DCAF15 helix and would not tolerate a 101 sidechain-bearing residue ( Fig. 1e) . At the interface between RBM39RRM2 and DCAF15 was 102 density that did not represent amino acid side chains and was tentatively assigned as E7820 ( Fig.   103 1e). While the proximity of RBM39 residue Met265, which when mutated to leucine abrogates 104 binding 14 , supports this assignment, the resolution of the cryo-EM map was insufficient for an 105 unambiguous interpretation of ligand binding. 106 We therefore engineered a minimal complex suitable for crystallographic studies. 107 Limited proteolysis experiments revealed that similarly sized fragments of DCAF15 were stably 108 associated with DDB1 after gel filtration ( Supplementary Fig. 4b ). This result indicated both 109 that DCAF15 contained an exposed, likely disordered, region available for proteolytic cleavage 110 and that distinct segments of DCAF15 could independently bind DDB1. Disorder prediction 111 further demonstrated a highly unstructured region of DCAF15 ( Supplementary Fig. 4c ), which 112 led us to design constructs of the N-terminal (residues 30-264) and C-terminal (residues 383-113 600) fragments of human DCAF15 (DCAF15split). Co-expression of these fragments with 114 DDB1∆B led to the formation of a soluble complex, that exhibited equivalent binding affinity for 115 RBM39 to full-length human DCAF15 ( Supplementary Fig. 4d,e ). Crystal structure of DCAF15 complex bound to RBM39RRM2 118 Crystals were obtained for a DDB1∆B-DCAF15split-DDA1-E7820-RBM39RRM2 complex, 119 and the structure was determined by molecular replacement with a final model refined to 2.9 Å 120 resolution ( Fig. 2a, Supplementary Table 2 ). To validate that the engineered DCAF15split 121 resembles the full-length DCAF15 structure, we docked the X-ray model into the cryo-EM map 20 122 and found that the crystal structure accounts for all of the full-length DCAF15 density as well as 123 density for E7820 ( Supplementary Fig. 3e,f) .
124
DCAF15split consists of two predominantly β-sheet containing domains ( Fig. 2b,c) , the N-125 terminal domain (NTD, residues 30-264) and the C-terminal domain (CTD, residues 383-600).
126
DCAF15 binds to DDB1 with a helix-loop-helix motif 21 , forming contacts with the two DDB1 β-127 propeller domains BPA and BPC and resembling the helix-loop-helix motif in CSA and DDB2 128 ( Supplementary Fig. 4a, Supplementary Fig. 5a,b) . DCAF15, unlike most other DDB1 and While β-sheets 2 and 3 have some resemblance to WD40 repeats, β-sheets 4 and 5 have unique 134 features ( Fig. 2b,c) . Preceding β-sheet 4 is a short helix (a4) angled ~ 45° away from the sheet, 135 before looping into β-strand 10 and 11. The terminal strands 12 and 14 of β-sheet 4 are 136 contributed by the DCAF15 CTD, creating an extended interface between the two domains. β-137 sheet 5 is stabilized by two a-helices (DCAF15 a5 and a6), and a7 helix sits on the opposite 138 side forming the major interactions with RBM39RRM2. The overall shape of DCAF15 is clamp-139 like and embraces RBM39RRM2 on the concave surface. The small protein DDA1 is commonly associated with CRL4 complexes 23,24 , and 141 knockout of DDA1 was found to reduce the indisulam-mediated degradation of RBM39 14 . In the 142 crystal and cryo-EM structures, DDA1 binds to the top of the DDB1 BPA before running down 143 the backside of the propeller (Fig. 1d, Fig. 3a) . At the bottom of the DDB1 BPA, DDA1 144 intercalates a β-strand in the DDB1 propeller, using several highly conserved residues (Fig. 3b) . 145 Adjacent to this β-strand is an a-helix that buries multiple DDA1 hydrophobic residues (Leu55, 146 Leu56, Leu59, and Trp63) in DCAF15 (Fig. 3b) . Given that DDA1 is a core CRL4 component 147 associating with many different substrate receptors 23,25 , the extent of the DCAF15 interactions 148 are unexpected and suggest that the DDA1 helix represents a plastic binding module for other 149 DCAFs. We measured the affinity of E7820 to recombinant DDB1-DCAF15 and DDB1-150 DCAF15-DDA1, as well as the ability of these complexes to bind to RBM39RRM2. While the 151 affinity of E7820 to DCAF15 was not altered by the presence of DDA1, the apparent affinity to 152 RBM39RRM2 was strengthened ~ 3-fold with an KD app of 0.62 µM ( Fig. 3c-e 
Aryl-sulfonamides interact primarily with DCAF15
156 E7820 binds in a shallow pocket at the interface between DCAF15-NTD and DCAF15-157 CTD situated in a weakly conserved surface groove proximal to DDB1 ( Fig. 4, Supplementary 158 Fig. 5c-e ). While the placement of E7820 is firmly supported by the electron density 159 ( Supplementary Fig. 6a,b) , we further validated the arrangement of the ligand through 160 anomalous diffraction and a UV-crosslinking probe ( Supplementary Fig. 6c-h) . E7820 is 161 sandwiched in a hydrophobic pocket between DCAF15 and RBM39RRM2, with the indole facing 162 Met265 of RBM39. Notably, the RBM39 Met265Leu mutation was found to confer resistance to 163 9 E7820-mediated degradation 14 , which is in accordance with the sulfur-p interaction observed in 164 the structure. The two sulfonyl oxygens of E7820 form hydrogen bonds with the backbone amide 165 nitrogens of DCAF15 Ala234 and Phe235, while the indole nitrogen and sulfonamide nitrogen 166 form extensive water-mediated hydrogen bonds with the sidechain oxygens of RBM39 Thr262 167 and Asp264. Additional hydrogen bonds between the indole nitrogen and backbone carbonyl 168 oxygen of DCAF15 Phe231, together form the core pharmacophore. The C4 methyl of E7820 169 forms hydrophobic interactions with Val477 and Val556 of DCAF15 (Fig. 4a,c) , and swapping 170 the methyl for a hydrogen, as in indisulam or desmethyl-E7820, results in a significant loss of 171 DCAF15 binding ( Supplementary Fig. 6i ). The phenyl ring forms a T-shaped p-p interaction 172 with DCAF15 Phe235 and otherwise is situated in a spacious pocket allowing for structural 173 diversity as observed in indisulam and tasisulam. 174 Finally, we obtained structures of the related but structurally distinct analogs indisulam 175 and tasisulam to 2.9 Å resolution, respectively ( Fig. 4d, Supplementary Fig. 6j,k) . We find that 176 indisulam and tasisulam bind DCAF15 in an overall configuration similar to E7820, maintaining 177 the backbone hydrogen bonds from the sulfonyl groups to DCAF15 Ala234 and Phe235 and the 178 water mediated hydrogen bonds. However, the methyl to hydrogen substitution at C4 in Supplementary Fig. 6j,k) . These differences in indisulam and tasisulam help to explain their 182 significant loss in affinity for DCAF15, while maintaining the ability to recruit RBM39 for 183 degradation (Fig. 1a,c) . The weak affinity of aryl-sulfonamides for DCAF15 ( Supplementary Fig. 1c,f) suggests 187 that protein-protein contacts between DCAF15 and RBM39RRM2 stabilize the interaction. 188 RBM39RRM2 presents itself as a canonical RRM fold, comprised of a four-stranded anti-parallel 189 b-sheet (b1 -b4) stacked on two a-helices (a1 and a2) ( Fig. 2a) and interacts with DCAF15 190 predominantly via the two a-helices. The RBM39RRM2 a1 helix docks into the surface groove on 191 DCAF15 that also harbors the E7820 binding site and forms contacts with DCAF15 and E7820. 192 The RBM39RRM2-DCAF15 interface comprises ~1,150 Å 2 and spans the DCAF15 NTD and 193 CTD (Fig. 5a) . The binding groove is not conserved (Supplementary Fig. 5e ) and is dominated 194 by extensive hydrophobic interactions with the DCAF15 a7 helix in the CTD (Fig. 5b) . As was 195 observed in the cryo-EM structure (Fig. 1e) , the tight packing of the interface would not allow a 196 side chain-bearing residue at RBM39 Gly268, such that a Gly268Val mutation completely 197 abrogates RMB39RRM2 recruitment to DCAF15 (Supplementary Fig. 6l ). The interface includes 198 four salt bridges between DCAF15 Arg574, Arg178, Arg160, and Asp174 and RBM39 Asp264, 199 Glu271, and Arg275 respectively, and side chain hydrogen bonds between DCAF15 Ser546 and 200 RBM39 Gln310, respectively ( Fig. 5b ). An additional indisulam resistance mutation in RBM39, 201 Glu271Gln 14 , is likely explained by a loss in the salt bridge interaction with DCAF15 202 (Supplementary Fig. 6m ). An extended network of backbone hydrogen bonds further stabilizes 203 the DCAF15-RBM39 interface (Supplementary Fig. 6n ).
205
Aryl-sulfonamides selectively degrade of RBM39 and RBM23 206 As many RRM domains are structurally highly similar and since RBM39 interacts with 207 DCAF15 predominantly through two conserved a-helices in its second RRM, we considered 208 whether other RRM-containing proteins would be targeted by DCAF15 and E7820. To assess the 209 11 degradome of E7820, we performed unbiased mass spectrometry-based proteomics experiments 210 and found only RBM23 to be degraded in addition to RBM39 out of ~ 11,000 proteins detected 211 ( Fig. 5c ). Sequence analysis revealed that the second RRM domain of RBM23 (RBM23RRM2) is 212 nearly identical to RBM39RRM2, with 100% sequence identity across all key residues that form 213 contacts with DCAF15 and E7820 (Fig. 5d) . Consequently, we found comparable binding 214 affinity for RBM23RRM2 to that observed for RBM39RRM2 ( Fig. 5e) . Cullin-RING ligases of the 215 CRL4 family tolerate a diverse set of substrate receptors but typically present their substrates in a 216 canonical position 21, 26 . When superimposed with a Cullin-RING ligase complex (pdb: 4a0k), a 217 model of the full CRL4 DCAF15 ligase bound to RBM39 can be constructed. RBM39RRM2 is bound 218 to a face of DCAF15 that is not directly opposed to RBX1 (Fig. 6a) , however the N-and C-219 termini of RBM39 are positioned towards RBX1, and could tolerate additional domains at both 220 positions. Furthermore, in contrast to CRBN, the ligand and substrate pocket of DCAF15 is not 221 conserved ( Fig. 6b) , suggesting that the topological and evolutionary constraints on developing 222 molecular glue degraders are rather flexible. Our work identifies DDA1 as an integral component of the CRL4 DCAF15 ubiquitin ligase, 255 and we demonstrate how DDA1 serves as an additional scaffolding subunit of a functional CRL4 256 complex. In the case of CRL4 DCAF15 , DDA1 binds to the top of the BPA subunit of DDB1 and 257 forms extensive contacts with the backside of DDB1 before connecting to DCAF15 through an 258 a-helix enforcing the overall structure of the complex. The presence of DDA1 causes increased 259 E7820-dependent binding of DCAF15 to RBM39RRM2, which is in accordance with DDA1 260 knockout resulting in partial rescue of RBM39 degradation in cells 14 . It is conceivable that 261 DDA1 will serve as a scaffolding protein in other CRL4 complexes, but more work is needed to 262 understand the role of DDA1 in CRL4 regulation and its potential interplay with other CRL 263 regulators such as the COP9 signalosome (CSN) and CAND1. 264 In summary, our work significantly expands our understanding of general principles of 265 molecular glue degraders. We show how binders targeted to interfaces with significant sidechain 266 interactions between receptor and substrate result in very selective agents. This is in contrast to 267 IMiDs, which bind a conserved pocket in CRBN and only contribute minor backbone 268 interactions to the interface, resulting in highly poly-targeted molecules 9,10 . While close analogs 269 of E7820 are unlikely to target a broad set of RRM domains, the structural complementarity 270 between DCAF15 and the canonical RRM fold suggests that novel chemical matter to target 271 other RRM containing proteins to CRL4 DCAF15 will likely be obtainable. Importantly, our 272 structural characterization further supports the concept that compatible interfaces are more likely 273 to occur between unrelated proteins than we may have anticipated. As such, prospective screens 
